Pregnancy and the puerperium are well-established risk factors for deep vein thrombosis (DVT) and pulmonary embolism (PE), which are collectively referred to as venous thromboembolic disease (VTE). Treatment of VTE in pregnant patients is unique in several ways. (See "Use of anticoagulants during pregnancy and postpartum".)
●Warfarin is generally not used, particularly in the first trimester, because it may be teratogenic.
●Synthetic heparin pentasaccharides (eg, fondaparinux, idraparinux) are avoided because due to a paucity of safety data for these agents.
●Monitoring of anticoagulant activity tends to be more vigilant because less is known about the appropriate dosing of anticoagulants during pregnancy.
Treatment of VTE during pregnancy and the puerperium will be reviewed here [1-6]. The epidemiology, pathogenesis, diagnosis, and prevention of VTE during pregnancy and the puerperium are discussed separately. (See "Deep vein thrombosis in pregnancy: Epidemiology, pathogenesis, and diagnosis" and "Deep vein thrombosis and pulmonary embolism in pregnancy: Prevention".)